Recombinant CD59 Fc-Fused Nanobody (VF0131)
Ucallm_WN0424
$365.00
Product details
Background:This gene encodes a cell surface glycoprotein that regulates complement-mediated cell lysis, and it is involved in lymphocyte signal transduction.This protein is a potent inhibitor of the complement membrane attack complex, whereby it binds complement C8 and/or C9 during the assembly ofThis complex, thereby inhibiting the incorporation of multiple copies of C9 into the complex, which is necessary for osmolytic pore formation.This protein also plays a role in signal transduction pathways in the activation of T cells. Mutations inThis gene cause CD59 deficiency, a disease resulting in hemolytic anemia and thrombosis, and which causes cerebral infarction. Multiple alternatively spliced transcript variants, which encode the same protein, have been identified forThis gene. [provided by RefSeq, Jul 2008]
Specifications
| Size | 100μL |
| Target | CD59 |
| Reactivity | Human |
| Applications | ELISA, FC |
| MW(Calculated) | |
| MW(Observed) | |
| Host Species | |
| Isotype | IgG2a,Kappa |
| Conjugate/Modification | Unmodified |
| Recommended Dilution Ratio | ELISA 1:5000-100000; Flow Cyt 1-2μg/Test |
| Formulation | Phosphate-buffered solution |
| Purification | Recombinant Expression and Affinity purified |
| Storage | -15°C to -25°C/1 year(Avoid freeze / thaw cycles) |
| Concentration | Please check the information on the tube |
| Clonality | |
| Clone Number | VF0221 |
| Immunogen | Purified recombinant Human CD59 |
| Specificity | This recombinant monoclonal antibody can detects endogenous levels of CD59 protein. |
| Gene Name | CD59 MIC11 MIN1 MIN2 MIN3 MSK21 |
| Protein Name | CD59 glycoprotein (1F5 antigen) (20 kDa homologous restriction factor) (HRF-20) (HRF20) (MAC-inhibitory protein) (MAC-IP) (MEM43 antigen) (Membrane attack complex inhibition factor) (MACIF) (Membrane inhibitor of reactive lysis) (MIRL) (Protectin) (CD antigen CD59) |
| Other Name | CD59; / MIC11; / MIN1; / MIN2; / MIN3; / MSK21; / CD59 glycoprotein; / 1F5 antigen; / 20 kDa homologous restriction factor; / HRF-20; / HRF20; / MAC-inhibitory protein; / MAC-IP; / MEM43 antigen; / Membrane attack complex inhibition factor; / MACIF; / Membrane inhibitor of reactive lysis; / MIRL; / Protectin; / CD59; / CD59 nanobody |
| Species | Human |
| Gene ID | 966 |
| Uniprot | P13987 |
| Species.1 | |
| Gene ID.1 | |
| Uniprot.1 | |
| Species.2 | |
| Gene ID.2 | |
| Uniprot.2 | |
| Cellular Localization | Cell membrane; Lipid-anchor, GPI-anchor. Secreted. Soluble form found in a number of tissues. |
| Tissue Expression | Expressed in NK cell subsets (at protein level) (PubMed:21825173, PubMed:94322, PubMed:948526). Expressed in memory/effector CD8-positive alpha-beta T cell subsets (at protein level) (PubMed:12387742, PubMed:2952657). Expressed in melanoma-specific cytotoxic T cell clones (at protein level) (PubMed:948526). Expressed in terminally differentiated cytotoxic gamma-delta T cells (at protein level) (PubMed:2952657). KLRD1-KLRC1 and KLRD1-KLRC2 are differentially expressed in NK and T cell populations, with only minor subsets expressing both receptor complexes (at protein level) (PubMed:2952657). |
| Signaling_pathway | Organismal Systems >> Immune system >> Hematopoietic cell lineage;Organismal Systems >> Immune system >> Complement and coagulation cascades |
| Research Areas | |
| Function | Disease:Defects in CD59 are the cause of CD59 deficiency [MIM:612300].,Potent inhibitor of the complement membrane attack complex (MAC) action. Acts by binding to the C8 and/or C9 complements of the assembling MAC, thereby preventing incorporation of the multiple copies of C9 required for complete formation of the osmolytic pore. This inhibitor appears to be species-specific. Involved in signal transduction for T-cell activation complexed to a protein tyrosine kinase.,The soluble form from urine retains its specific complement binding activity, but exhibits greatly reduced ability to inhibit MAC assembly on cell membranes.,online information:CD59 mutation db,PTM:Glycated. Glycation is found in diabetic subjects, but only at minimal levels in nondiabetic subjects. Glycated CD59 lacks MAC-inhibitory function and confers to vascular complications of diabetes.,PTM:N- and O-glycosylated. The N-glycosylation mainly consists of a family of biantennary complex-type structures with and without lactosamine extensions and outer arm fucose residues. Also significant amounts of triantennary complexes (22%). Variable sialylation also present in the Asn-43 oligosaccharide. The predominant O-glycans are mono-sialylated forms of the disaccharide, Gal-beta-1,3GalNAc, and their sites of attachment are probably on Thr-76 and Thr-77. The GPI-anchor of soluble urinary CD59 has no inositol-associated phospholipid, but is composed of seven different GPI-anchor variants of one or more monosaccharide units. Major variants contain sialic acid, mannose and glucosamine Sialic acid linked to an N-acetylhexosamine-galactose arm is present in two variants.,similarity:Contains 1 UPAR/Ly6 domain.,subcellular location:Soluble form found in a number of tissues.,subunit:Interacts with T-cell surface antigen CD2., |
Please login to post questions
Related products
